Aiosyn, a startup dedicated to detecting pathologies with AI, raises €2.4 million

The Netherlands-based startup closed a €2.4 million (approximately $2.8 million USD) funding round led by TNO Ventures, Oost NL, LUMO Labs and Health Innovations. Following this round, they also announced a partnership with TNO, an organization dedicated to research and technology.

Founded in 2021, by Patrick de Boer, Jeroen van der Laak, Wouter Bulten and David Téllez, Aiosyn uses deep learning algorithms to analyze digital pathology images. With this technology, they aim to improve the diagnosis of various diseases, such as cancer, and contribute to more specific and personalized treatments. They also seek to streamline laboratory analysis processes, enabling much faster diagnoses.

Aiosyn already offers three software programs focused on areas such as diagnostic quality, mitotic figure counting and sample analysis. They also provide specialized services for clients, aiming to improve workflows by using artificial intelligence to address areas that are often underserved through their digital platform.

With this new funding, the company plans to introduce new AI-powered digital pathology biomarkers, add tools for preclinical image analysis, and continue advancing its clinical validation to establish itself in the market.

Founders: Patrick de Boer, Jeroen van der Laak, Wouter Bulten, David Téllez

Sources: Aiosyn, Crunchbase